|
業務類別
|
Biotechnology |
|
業務概覽
|
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology. |
| 公司地址
| 1150 Marina Village Parkway, Alameda, CA, USA, 94501 |
| 電話號碼
| +1 510 626-8587 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.scribetx.com |
| 員工數量
| 89 |
| Dr. Svetlana Lucas, PhD |
Chief Business Officer |
-- |
02/07/2026 |
| Dr. Benjamin L. Oakes, PhD |
President, Chief Executive Officer and Director |
-- |
02/07/2026 |
| Mr. David L. Parrot, M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
-- |
02/07/2026 |
|
|
| Dr. Carl L. Gordon, C.F.A.,PhD |
Independent Director |
02/07/2026 |
| Dr. Behzad Aghazadeh, PhD |
Independent Director |
02/07/2026 |
| Dr. Benjamin L. Oakes, PhD |
President, Chief Executive Officer and Director |
02/07/2026 |
| Mr. James Watson, M.B.A. |
Independent Director |
02/07/2026 |
|
|
|
|
